| Thompson, John |
NCT05307341: Improving Pain Management and Decreasing LOS After Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) |
|
|
| Recruiting | 4 | 100 | US | sufentanil, sufentanil (DSUVIA) | More Foundation | Pain | 06/23 | 06/23 | | |
NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). |
|
|
| Recruiting | 2 | 246 | US | Active Comparator CT1812, Placebo Comparator | Cognition Therapeutics | Age-Related Macular Degeneration | 07/27 | 08/27 | | |
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation |
|
|
| Recruiting | 1/2 | 230 | Europe, US, RoW | PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79 | PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer | 03/26 | 07/26 | | |
NCT03377569: Subcortical Oscillations in Human Sleep Dysregulation |
|
|
| Active, not recruiting | N/A | 15 | US | Sleep, PD and DBS | University of Colorado, Denver | Parkinson Disease, REM Behavior Disorder | 08/20 | 12/24 | | |
NCT04620551: Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease |
|
|
| Active, not recruiting | N/A | 20 | US | Sub-clinical stimulation | University of Nebraska, Stanford University, University of Colorado, Denver, University of Pennsylvania | Parkinson Disease, Sleep Fragmentation | 06/24 | 06/24 | | |
| Gonzalez, Maria Jesus |
ASPIRE, NCT04118088: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula |
|
|
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
NCT05357989: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
|
|
| Completed | 3 | 523 | Europe, US | buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo | Annovis Bio Inc., TFS Trial Form Support | Parkinson's Disease, Idiopathic | 12/23 | 12/23 | | |
| Recruiting | 2 | 70 | Europe | Ascorbic acid, Vitamin C, 0.9% Saline solution, Saline | Hospital Universitario Ramon y Cajal | Liver Transplantation, Postreperfusion Syndrome, Ascorbic Acid | 06/23 | 07/23 | | |
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults |
|
|
| Active, not recruiting | 2 | 797 | Canada, US, RoW | ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline | AEON Biopharma, Inc., PPD | Migraine | 06/24 | 09/24 | | |
NCT03340129: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) |
|
|
| Recruiting | 2 | 218 | Europe, RoW | Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy | Melanoma Institute Australia, Bristol-Myers Squibb | Melanoma Stage Iv | 08/24 | 08/25 | | |
| Recruiting | 2 | 68 | Europe | Adagrasib | ETOP IBCSG Partners Foundation, Mirati Therapeutics Inc. | NSCLC Stage IV, KRAS P.G12C | 10/25 | 03/26 | | |
STX-001-01, NCT06249048: Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab |
|
|
| Recruiting | 1/2 | 108 | US, RoW | STX-001, Keytruda®, Pembrolizumab | Strand Therapeutics Inc. | Advanced Solid Tumor | 05/27 | 11/28 | | |
NCT04232696: Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI) |
|
|
| Active, not recruiting | N/A | 242 | Europe, US | Neuspera Implantable Sacral Nerve Stimulation System | Neuspera Medical, Inc. | Urinary Urgency Incontinence | 07/24 | 12/26 | | |
| Recruiting | N/A | 639 | Europe | | University Hospital, Strasbourg, France | COVID-19 | 12/23 | 12/23 | | |
| Recruiting | N/A | 80 | Europe, US | Oxygen | Boston Children's Hospital, Massachusetts General Hospital, Massachusetts Institute of Technology, National Institute for Biomedical Imaging and Bioengineering (NIBIB), Madrid-MIT M+Visión Consortium | Intrauterine Growth Restriction | 09/25 | 09/26 | | |
| Completed | N/A | 5694 | Europe | | University Hospital, Strasbourg, France | COVID-19 | 04/22 | 06/22 | | |
| Long, Georgina |
| Active, not recruiting | 3 | 423 | Europe, US, RoW | Neoadjuvant ipilimumab + nivolumab, Yervoy + Opdivo, Adjuvant nivolumab, Opdivo | The Netherlands Cancer Institute, Bristol-Myers Squibb | Malignant Melanoma Stage III | 01/24 | 12/28 | | |
ACTRN12613000737730: An open label, single centre, phase II pilot study of neoadjuvant dabrafenib + trametinib in patients with resectable AJCC Stage IIIB-C BRAF V600 mutation positive melanoma |
|
|
| Active, not recruiting | 2 | 35 | | | Melanoma Institute Australia, GlaxoSmithKline Australia | Melanoma | | | | |
ACTRN12614001315606: A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases (ABC - Anti-PD1 Brain Collaboration Study) |
|
|
| Active, not recruiting | 2 | 75 | | | Melanoma Institute Australia , Melanoma Institute Australia | Melanoma Brain Metastases, Melanoma | | | | |
Neo Combi, NCT01972347: Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma |
|
|
| Active, not recruiting | 2 | 35 | RoW | Dabrafenib, GSK2118436, Trametinib, GSK1120212 | Melanoma Institute Australia | Melanoma | 05/17 | 05/24 | | |
|
| Active, not recruiting | 2 | 76 | RoW | Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016 | Melanoma Institute Australia, Melanoma and Skin Cancer Trials Limited, Bristol-Myers Squibb | Melanoma, Brain Metastases | 09/17 | 12/28 | | |
NeoTrio, NCT02858921: Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Dabrafenib, Tafinlar, Trametinib, Mekinist, Pembrolizumab, Keytruda | Melanoma Institute Australia, Merck Sharp & Dohme LLC, Novartis | Melanoma | 01/22 | 11/24 | | |
Neo PeLe, NCT04207086: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma |
|
|
| Active, not recruiting | 2 | 21 | RoW | Pembrolizumab, Keytruda, Lenvatinib, Lenvima | Melanoma Institute Australia, Merck Sharp & Dohme LLC | Melanoma Stage III | 01/23 | 01/33 | | |
| Recruiting | 2 | 20 | RoW | Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination, Opdualag | Melanoma Institute Australia, Bristol-Myers Squibb | Merkel Cell Carcinoma | 04/26 | 04/34 | | |
| Terminated | 2 | 205 | Europe, US, RoW | ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda | Seagen Inc., Merck Sharp & Dohme LLC | Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma | 11/23 | 11/23 | | |
NCT03340129: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) |
|
|
| Recruiting | 2 | 218 | Europe, RoW | Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy | Melanoma Institute Australia, Bristol-Myers Squibb | Melanoma Stage Iv | 08/24 | 08/25 | | |
Neo ReNi II, NCT05418972: A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma |
|
|
| Recruiting | 2 | 20 | RoW | Relatlimab and nivolumab fixed dose combination (FDC), Opdualag | Melanoma Institute Australia, Bristol-Myers Squibb | Stage II Melanoma | 12/24 | 12/34 | | |
KEYNOTE-D36, NCT05309421: A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma |
|
|
| Recruiting | 2 | 90 | RoW | EVX-01, Pembrolizumab 25 MG/ML, Keytruda | Evaxion Biotech A/S, Merck Sharp & Dohme LLC | Melanoma Stage III, Melanoma Stage IV | 06/25 | 07/25 | | |
KEYNOTE-E40, NCT05280314: Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors |
|
|
| Recruiting | 2 | 60 | Europe, US, RoW | IO102-IO103, Pembrolizumab KEYTRUDA® | IO Biotech, Theradex, Almac, Merck Sharp & Dohme LLC | Melanoma, Squamous Cell Carcinoma of Head and Neck | 04/25 | 01/27 | | |
I-MAT, NCT04291885: Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma |
|
|
| Recruiting | 2 | 132 | RoW | Avelumab, anti-PD-L1, Bavencio, Placebo | Melanoma and Skin Cancer Trials Limited | Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Merkel Cell Carcinoma, Stage III, Neuroendocrine Tumors, Carcinoma Neuroendocrine Skin | 04/27 | 04/28 | | |
| Withdrawn | 2 | 44 | RoW | Pembrolizumab, Keytruda, Lenvatinib, Lenvima | Melanoma Institute Australia, Merck Sharp & Dohme LLC | Mucosal Melanoma | 05/26 | 05/36 | | |
| Recruiting | 2 | 1000 | RoW | Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study | Melanoma Institute Australia, Novartis | Melanoma | 07/27 | 12/28 | | |
NCT04834973: A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma |
|
|
| Terminated | 1/2 | 3 | RoW | tigilanol tiglate, EBC-46, pembrolizumab, Keytruda | QBiotics Group Limited, Merck Sharp & Dohme LLC | Melanoma | 07/22 | 07/22 | | |
| Spillane, Andrew |
| Active, not recruiting | 3 | 634 | | | Melanoma and Skin Cancer Trial, Friends of the Mater Foundation, Cancer Council NSW, Melanoma Institute Australia | Metastatic melanoma | | | | |
| Active, not recruiting | 3 | 634 | Europe, RoW | Inguinal Lymphadenectomy, Ilio-inguinal Lymphadenectomy | Melanoma and Skin Cancer Trials Limited, Cancer Council New South Wales, Melanoma Institute Australia | Metastatic Melanoma to the Groin Lymph Nodes | 10/19 | 08/30 | | |
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma |
|
|
| Recruiting | 3 | 2998 | Europe, Canada, US, RoW | Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin | Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre | Cutaneous Melanoma, Stage II | 12/29 | 12/34 | | |
| Recruiting | N/A | 1167 | Europe, RoW | Omission of radiation therapy | Breast Cancer Trials, Australia and New Zealand, Breast International Group, ETOP IBCSG Partners Foundation | Early Stage Breast Carcinoma | 10/25 | 04/26 | | |
| Menzies, Alexander |
ACTRN12616001187437: Molecular Profiling and Matched Targeted Therapy for Patients with Metastatic Melanoma (MatchMel) |
|
|
| Not yet recruiting | 2 | 1000 | | | Melanoma Institute Australia, Melanoma Institute Australia, National Health and Medical Research Council | Metastatic Melanoma | | | | |
NCT03340129: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) |
|
|
| Recruiting | 2 | 218 | Europe, RoW | Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy | Melanoma Institute Australia, Bristol-Myers Squibb | Melanoma Stage Iv | 08/24 | 08/25 | | |
BELLA, NCT04739670: Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer |
|
|
| Recruiting | 2 | 31 | RoW | Atezolizumab, Bevacizumab, Gemcitabine, Carboplatin | Peter MacCallum Cancer Centre, Australia | Metastatic Triple Negative Breast Cancer | 09/25 | 09/25 | | |
| Smith, Elizabeth |
ENTRAIN, NCT06227780: Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental Disorders |
|
|
| Recruiting | N/A | 180 | US | Alpha Auditory Entrainment, Alpha Brainwave Entrainment, Alpha Binaural Beats, Pulsed Sound Stimulation, Sonic Entrainment, Sham | Children's Hospital Medical Center, Cincinnati, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Fragile X Syndrome, Autism Spectrum Disorder, Autistic Disorder, Asperger Syndrome | 05/27 | 05/28 | | |
NCT06088589: Speech-in-noise Perception in Autism and Fragile X |
|
|
| Not yet recruiting | N/A | 60 | NA | Mismatch negativity | Children's Hospital Medical Center, Cincinnati | Autism Spectrum Disorder, Fragile X Syndrome | 10/24 | 10/24 | | |
NCT05957549: Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG |
|
|
| Recruiting | N/A | 120 | US | Speech discrimination | Children's Hospital Medical Center, Cincinnati | Fragile X Syndrome | 09/26 | 08/27 | | |
| Lee, Jenny |
Keynote- PNC-34, NCT04811027: Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC |
|
|
| Active, not recruiting | 2 | 171 | Europe, US, RoW | Eftilagimod alpha, IMP321, Efti, Eftilagimod alfa, Pembrolizumab, Keytruda, MK-3475 | Immutep S.A.S., Merck Sharp & Dohme LLC | HNSCC | 03/24 | 03/25 | | |
|
| Recruiting | 2 | 27 | RoW | Pembrolizumab, External Beam Radiation Therapy, Radical Neck Dissection | Queensland Health, Merck Sharp & Dohme LLC | Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer | 06/25 | 06/27 | | |
I-MAT, NCT04291885: Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma |
|
|
| Recruiting | 2 | 132 | RoW | Avelumab, anti-PD-L1, Bavencio, Placebo | Melanoma and Skin Cancer Trials Limited | Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Merkel Cell Carcinoma, Stage III, Neuroendocrine Tumors, Carcinoma Neuroendocrine Skin | 04/27 | 04/28 | | |
NCT04121806: Diet Intervention Treatment for Active Ulcerative Colitis |
|
|
| Recruiting | N/A | 20 | Canada | UC intervention diet | Mount Sinai Hospital, Canada, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Colitis, Ulcerative | 09/23 | 09/23 | | |
| Long, Georgianna |
| No trials found |
| Salatino, Natalie |
| No trials found |
